For over 25 years, Celerion's bioanalytical laboratories have been providing small and large molecule bioanalytical services for a variety of chemical entities, including biomarkers, peptide analysis, oligonucleotides, pharmacokinetic and immunogenicity testing and cell-based assays. Our bioanalytical facilities in Lincoln, Nebraska, USA and Zurich, Switzerland are ideally located to support North American, European and Asian discovery, preclinical and clinical development programs. Our scientists have an average of over 15 years of experience. This experience is engaged in ensuring that high quality and robust assays are developed and validated according to stringent internal SOPs and industry requirements. These methods support the drug development pipeline from discovery support to first-in-human, proof-of-concept and large scale multi-site patient trials, on through post-marketing studies. Our breadth of bioanalytical capabilities includes small and large molecule LC-MS/MS, ICP-MS, ligand binding services, cell-based assay and immunogenicity testing services. Our global laboratory network provides the flexibility to ensure we deliver on your scheduling and capacity challenges in a timely manner. Industry aligned incurred sample reproducibility (ISR) guidelines ensure that we are delivering more accurate and reproducible assay results with limited rework. High-quality processes, reinforced by our Quality Management System (QMS) and a global focus on continuous improvement, ensure that top-quality compliant data is delivered on time to meet clients' expectations. Integration with Celerion's clinical facilities enables 24-hour turnaround from last sample to pharmacokinetic analysis for rapid dose escalation decision making.
Our scientific personnel are dedicated to providing the highest quality results, within your cost and time expectations. By first demanding excellence of ourselves, we are committed - now more than ever - to putting our minds to work for our clients.
At Celerion, we foster a culture of continuous improvement, ensuring that top quality, compliant bioanalytical data is delivered to clients on time.
Our bioanalytical teams proudly meet clients' expectations by consistently delivering on a target of 95% on-time performance - from method development to a Quality Assured bioanalytical report. Our consistent batch success rate of 95% minimizes rework for clients' programs to allow for more efficient movement through the various phases of clinical research. – less – More from ZoomInfo »